Episode 9: Among the topics: Cardiac involvement in Fabry's disease - Anti-thrombotic therapy post PCI: DAPT in 2023

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

• Cardiology This Week: A concise summary of recent studies
• Cardiac involvement in Fabry's Disease
• Anti-thrombotic therapy post PCI: DAPT in 2023
• Mythbusters: Powernap for heart health

Host: Rick Grobbee
Guests: Perry Elliott, Nicolle Kraenkel, Roxana Mehran and Franz Weidinger

Want to watch that episode? Go to: https://esc365.escardio.org/event/896

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes.
The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.
Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Franz Weidinger have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Sanofi.

Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll;
personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, WebMD; Equity <1% in Applied Therapeutics, Elixir Medical, Stel, ControlRad (spouse); Scientific Advisory Board for AMA, ACC (BOT Member, SC Member CTR Program), SCAI (Women in Innovations Committee Member), JAMA Cardiology Associate Editor; Faculty CRF (no fee).

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer- Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.